Regeneron
Trade Regeneron 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About REGN
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara.
REGN Key Statistics
Stock Snapshot
The current Regeneron(REGN) stock price is $748.56, with a market capitalization of 77.07B. The stock trades at a price-to-earnings (P/E) ratio of 18.28 and offers a dividend yield of 0.50%.
During the trading session on 2026-10-09, Regeneron(REGN) shares reached a daily high of $750.00 and a low of $733.70. At a current price of $748.56, the stock is +2.0% higher than the low and still -0.2% under the high.
Trading volume for Regeneron(REGN) stock has reached 51.56K, versus its average volume of 751.24K.
Over the past 52 weeks, Regeneron(REGN) stock has traded between a high of $859.34 and a low of $541.00.
Over the past 52 weeks, Regeneron(REGN) stock has traded between a high of $859.34 and a low of $541.00.
REGN News
Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study. The phase 3 study titled “Phase 3 Evaluation of the Safety, Pharmacokinet...
RBC Capital analyst Brian Abrahams raised the firm’s price target on Regeneron (REGN) to $810 from $737 and keeps a Sector Perform rating on the shares as part...
Biohaven announced that it entered a clinical supply agreement with Regeneron to test BHV-1530 in combination with cemiplimab in patients with solid tumors, wit...
Analyst ratings
63%
of 30 ratingsMore REGN News
The latest announcement is out from Regeneron ( (REGN) ). On October 1, 2026, Regeneron and long-time partner Sanofi expanded their antibody collaboration thro...
Regeneron Pharmaceuticals reported early ubamatamab data in recurrent low-grade serous ovarian cancer and Phase 2 trevogrumab results in GLP-1 weight loss thera...
Regeneron Pharmaceuticals (REGN) just expanded its long-running immunology alliance with Sanofi, securing a US$1b upfront payment and potential milestones up to...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.